Overview

* Sanara Q3 revenue grows 22% yr/yr to $26.3 mln, missing analyst expectations

* Net income from continuing operations improved to $0.8 mln from a loss last year

* Company ceases Tissue Health Plus operations for strategic realignment

Outlook

* Company expects strong, sustainable revenue growth for remainder of 2025

Result Drivers

* SOFT TISSUE SALES - Revenue growth driven by 24% increase in sales of soft tissue repair products, including CellerateRX Surgical and BIASURGE

* STRATEGIC REALIGNMENT - Ceased operations of Tissue Health Plus to enhance operational efficiency and focus on core surgical business

* DISTRIBUTION NETWORK EXPANSION - Growth attributed to development of relationships with independent distributors and expansion into new healthcare facilities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $26.30 $26.60

Revenue mln mln (2

Analysts

)

Q3 EPS -$3.40

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Sanara Medtech Inc ( SMTI ) is $50.00, about 43.9% above its November 11 closing price of $28.04

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)